c-Mesenchymal-Epithelial Transition Factor Kinase Inhibitors

c-Met, also known as MET or mesenchymal-epithelial transition factor, is a prototype member of a subfamily of heterodimeric receptor tyrosine kinases, or RTKs, and it is the receptor for hepatocyte growth factor (HGF). The activation of MET can occur via ligand-independent or ligand-dependent mechanisms.

Mesenchymal-Epithelial Transition Factor

The binding of HGF to the MET extracellular domain leads to receptor multimerization, phosphorylation, and activation of MET-dependent signal transduction within the cell. Activation of the MET receptor results in the activation of downstream signals, including the mitogen activated phosphatidylinositol 3-kinase (PI3K/AKT) and protein kinase (ERK/MAPK) pathways, RAS and STAT3.

Dysregulated HGF/c-Met signaling promotes tumor growth, invasion, dissemination and angiogenesis. It is a driving factor for a number of malignancies. Dysregulated HGF/c-Met signaling has also previously been associated with resistance acquisition to some approved targeted therapies and poor clinical outcomes. So, c-Met kinase has emerged as a promising target for cancer drug development.

c-Met Kinase Inhibitors from BioVision

A range of therapeutic approaches which target the HGF/c-Met signaling pathway is being developed for targeted cancer therapy, among which small molecule inhibitors of c-Met kinase constitute the biggest effort within the pharmaceutical industry. BioVision is proud to provide numerous structurally diverse small molecule c-Met kinase inhibitors for research.

About BioVision Incorporated

BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area.

BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Feb 21, 2020 at 9:30 AM


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BioVision Incorporated. (2020, February 21). c-Mesenchymal-Epithelial Transition Factor Kinase Inhibitors. News-Medical. Retrieved on December 02, 2021 from https://www.news-medical.net/whitepaper/20190624/c-Mesenchymal-Epithelial-Transition-Factor-Kinase-Inhibitors.aspx.

  • MLA

    BioVision Incorporated. "c-Mesenchymal-Epithelial Transition Factor Kinase Inhibitors". News-Medical. 02 December 2021. <https://www.news-medical.net/whitepaper/20190624/c-Mesenchymal-Epithelial-Transition-Factor-Kinase-Inhibitors.aspx>.

  • Chicago

    BioVision Incorporated. "c-Mesenchymal-Epithelial Transition Factor Kinase Inhibitors". News-Medical. https://www.news-medical.net/whitepaper/20190624/c-Mesenchymal-Epithelial-Transition-Factor-Kinase-Inhibitors.aspx. (accessed December 02, 2021).

  • Harvard

    BioVision Incorporated. 2020. c-Mesenchymal-Epithelial Transition Factor Kinase Inhibitors. News-Medical, viewed 02 December 2021, https://www.news-medical.net/whitepaper/20190624/c-Mesenchymal-Epithelial-Transition-Factor-Kinase-Inhibitors.aspx.

Other White Papers by this Supplier